Cantor Fitzgerald: Raise the target price of Pfizer (PFE.US) from US$61 to US$75

$Pfizer (PFE.US)$ Analyst Louise Chen said that on Pfizer's upcoming investor day, the company's new crown vaccine and new crown oral drug Paxlovid will be the focus of attention. If the company’s management can guarantee the durability of vaccine sales and the peak sales potential of oral drugs, this may be a positive catalyst.

According to analysts, her peak sales potential for these two businesses is estimated to be between US$50 billion and US$60 billion. She pointed out that the rising number of new crown infections and concerns about the Ome Keron variant, and the weakened effectiveness of the existing new crown vaccine against the Ome Keron variant, can support her view; although there are other pharmaceutical companies in the Research on next-generation antibodies, but it may not be available until later in 2022.

Article excerpted from the US Stock Research Agency